- Trial phase
- Phase 3
- Time to market
- If Phase 3 PEAK succeeds, a BLA submission would follow. The company expects Pivotal Analysis 2 data in Q2 2027, suggesting a potential BLA filing in 2027 and potential approval in 2028, though no official timeline has been given.
- Why 7/10
- The next hard, dated catalyst is the topline data from Pivotal Analysis 1 of the Phase 3 PEAK trial (300-patient cohort, 24-week primary endpoint), expected in December 2026, roughly one month from today. KSI-101 is a major pipeline asset at Kodiak but not the sole value driver (the company also has Zenkuda (heading for BLA submission) and KOD) and KSI-501 (Phase 3 ALTO for DME), so the score is 7 rather than 8-10.
The December 2026 PEAK topline data is the key binary event to watch. If KSI-101 replicates the Phase 1b APEX signal (meaningful vision gains, rapid retinal drying) in the larger Phase 3 setting, it would validate the bispecific IL-6/VEGF approach and strengthen Kodiak's pipeline beyond Zenkuda. A miss or underwhelming result would be a significant negative given the elevated stock price and stretched cash position. The company's thin equity base ($12.6 million) and ~$66 million quarterly burn rate mean financing risk is high regardless of the readout outcome.
Price Chart
How It Works
KSI-101 is a bispecific protein drug injected into the eye that simultaneously blocks two disease pathways: IL-6 (a driver of inflammation) and VEGF (a driver of abnormal blood vessel growth and leakage). By targeting both pathways at once, it aims to treat macular edema (fluid buildup in the retina) caused by inflammatory conditions like uveitis, which standard anti-VEGF-only drugs may not fully address.
Trial Status
KSI-101 is in a global Phase 3 program consisting of two pivotal trials: PEAK (single cohort of 300 patients) and PINNACLE. The first 300-patient cohort in PEAK completed enrollment in August 2026, with topline data from the 24-week primary endpoint expected in December 2026 (Pivotal Analysis 1). A second 600-patient cohort across both PEAK and PINNACLE is also enrolling, with data expected in Q2 2027 (Pivotal Analysis 2). Prior Phase 1b APEX study data showed meaningful vision gains as early as week 4, with over 90% of patients achieving absence of macular edema and effects sustained through week 20 weeks after a single dose.
The Two-Sided Case
Upcoming Catalysts
- December 2026: Topline data from Phase 3 PEAK Pivotal Analysis 1 topline results (300 patients, 24-week primary endpoint)
- Q2 2027: Pivotal Analysis 2 data from combined PEAK and PINNACLE cohorts (600 patients)
- Q4 2026: Multi-indication BLA submission for Zenkuda (separate program, but relevant for company sentiment)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Kodiak Sciences Inc. 8-K KOD ·Originating report